Valuation: GI Dynamics, Inc.

Market Cap 440K 387K 360K 331K 621K 42.66M 632K 4.3M 1.68M 20.81M 1.65M 1.62M 72.18M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.88M 2.68M 2.46M 4.62M 318M 4.7M 32.04M 12.5M 155M 12.31M 12.05M 537M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 04/08/2025
Director of Finance/CFO 57 31/07/2025
Chief Tech/Sci/R&D Officer - 31/03/2023
Director TitleAgeSince
Chairman 67 20/10/2020
Director/Board Member - 19/10/2020
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
28/01/21 Free

Chief Executive Officer

11,075,869 3.8998%
28/01/21 Free

Chairman

1,384,483 0.4875%

Financials

2019 2020
Net sales - -
Net income -17.33M -15.24M -14.16M -13.03M -24.43M -1.68B -24.86M -169M -66.05M -819M -65.07M -63.66M -2.84B -11.14M -9.79M -9.1M -8.37M -15.69M -1.08B -15.97M -109M -42.44M -526M -41.81M -40.9M -1.82B
Net Debt 2.89M 2.54M 2.36M 2.17M 4.07M 280M 4.14M 28.21M 11M 136M 10.84M 10.6M 473M 2.84M 2.5M 2.32M 2.13M 4M 275M 4.07M 27.74M 10.82M 134M 10.66M 10.43M 465M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock